This webinar will explore how AI is revolutionizing antibody sequence prediction, optimizing candidate selection and simplifying the handling of complex datasets in ...

This Phase 1b/2, open-label, multicenter dose escalation and expansion combination study of ADG126 in combination with Merck’s (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA ® ...

Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...

Mississauga, Ontario Tuesday, January 21, 2025, 14:00 Hrs [IST] ...

With the commencement of Trump 2.0, the equity market experienced notable volatility, influenced by his administration's policy announcements. Yesterday during the inauguration, markets initially ...

CHENGDU, China I January 20, 2025 I Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”) has received marketing authorization in China from ...

Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks ...

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...

Canary Cure Therapeutics (Canary Global Inc.) has released preclinical results for its lead candidate, CCT-217, an siRNA therapeutic targeting cannabinoid CB1 receptor (CB1R) and zinc finger protein ...

Many of the most devastating infectious diseases are caused by RNA viruses and Model Medicines is working on one compound to ...

The global precision diagnostics and medicine market, valued at US$132.46 billion in 2023, is forecasted to grow at a robust CAGR of 11.1%, reaching US$145.53 billion in 2024 and an impressive US$246.